We present a retrospective study of long-term outcome and predictive factors of survival and relapse in 219 paediatric patients with acute lymphoblastic leukaemia (ALL) in second remission. They received allogeneic (allo) or autologous (auto) haemopoietic cell transplantation (HCT) depending on the availability of a matched sibling donor. The probability of event-free survival (EFS) for the total patient group was 0.35 þ 0.03 at 14 years. No significant differences were observed for EFS between allo-and auto-HCT: 0.39 þ 0.05 vs 0.32 þ 0.04 (P ¼ 0.43). A better EFS was seen in patients with a late relapse (LR) (P ¼ 0.06 and 0.02, for allogeneic and autologous respectively). Significantly better EFS was observed in allo-HCT patients under 10 years of age and in auto-HCT patients with leukocytes at diagnosis below 25 Â 109/l and late relapse. Predictive factors of failure in both groups were early relapse (ER), medullary relapse and age over 10 years. The probability of relapse (RP) for the total group of patients was 0.57 þ 0.03, and it was significantly higher in auto-HCT patients: 0.65 þ 0.04 vs 0.42 þ 0.06 (P ¼ 0.002). Factors predictive for relapse were medullary and early relapse, auto-HCT and WBC 425 Â 109/l at diagnosis. The intensive chemotherapy regimen presently used for childhood lymphoblastic leukaemia allows a prolonged disease-free survival in more than 70% of patients.
cell transplantation; children
The intensive chemotherapy regimen presently used for childhood lymphoblastic leukaemia allows a prolonged disease-free survival in more than 70% of patients. 1 Relapse is observed in approximately 20-25% of patients, mostly within the first 5 years after diagnosis. 2, 3 Optimal therapy for relapsed patients remains controversial in some areas. 4 With the use of intensive chemotherapy, 80-95% of patients achieved a complete second remission. However, less than 5% of the patients with an early relapse (during therapy or within 30 months of diagnosis) and 25-40% of those with a late relapse (after 6 months of completion of therapy or as of 30 months since diagnosis) are long-term survivors. [5] [6] [7] Allogeneic haemopoietic cell transplantation (allo-HCT) from a matched sibling donor has been shown to be superior to chemotherapy, especially for patients with an early relapse; [8] [9] [10] [11] [12] [13] for late isolated extramedullary relapse, chemotherapy alone may play a role. 14, 15 However, the lack of a compatible matched sibling donor limits the use of this treatment. The safety and efficacy of autologous HCT (auto-HCT) in children with acute lymphoblastic leukaemia (ALL) has been previously reported. [16] [17] [18] [19] [20] [21] [22] Comparison studies of auto-and allo-HCT have suggested different failure patterns, but comparable survival rates. Auto-HCT offers the advantages of an accelerated immunological recovery and the absence of graft-versus-host disease (GVHD) compared with allo-HCT. By contrast, a higher relapse rate is observed in patients receiving an autologous transplant. [23] [24] However, the heterogeneity of populations used for comparison (stage of disease, risk factors, prior therapy, conditioning regimens) makes it difficult to reach any conclusions which may be useful in therapeutic decision-making.
We retrospectively analysed the predictive factors of event-free survival (EFS) and relapse in 219 children diagnosed with ALL in second complete remission (CR), who underwent an allo-or auto-HCT in eight GETMON centres, between 1983 and 1998. We also compared the outcome in the two populations (autologous and allogeneic), which had no discernible differences other than the availability of a matched sibling donor.
Patients and methods
Results obtained with HCT in 219 patients diagnosed of ALL in second CR are presented. Transplants were performed between April 1983 and December 1998 in eight paediatric centres participating in GETMON. Depending on the availability or lack of a matched sibling donor, 90 patients underwent an allo-HCT and 129 an auto-HCT. No children with high-risk cytogenetic anomalies (translocations 9:22 or 4:11) were included in our series as these patients are considered to be very high risk and are transplanted in first CR.
All patients had received multiagent chemotherapy as first-line therapy, according to the current protocols at their centre; SHOP-89, SHOP-94 and PHETEMA 84, 89 and 93. [25] [26] [27] Treatment after relapse in all patients consisted of vincristine, prednisone, asparaginase, an anthracycline and intrathecal chemotherapy. Patients with extramedulary relapses (CNS or testes) also received radiotherapy to the affected areas.
Relapse was defined as early when occurring within 30 months of diagnosis and late when occurring later than 30 months after diagnosis (ie after 6 months since cessation of therapy). All patients with isolated extramedullary relapse included in this study had an early relapse.
Allo-HCT were performed from a matched sibling donor. The source of the haemopoietic graft was bone marrow in 76/90 (85%) of transplants and peripheral blood cells in the rest. Conditioning consisted of cyclophosphamide 120 mg/m 2 and fTBI 12.5 Gy in most patients (80%) ( Table 1 ). In total, 44 patients did not received irradiation in their conditioning. In total, 33 were under 3 years of age and TBI was avoided to prevent the undesirable sequelae. 28, 29 In 11 patients over this age, irradiation was not available at the required time at the treating institution. These 44 patients received busulphan 16 mg/kg and cyclophosphamide as above 7VP-16 45 mg/ kg; in patients under 6 years of age the busulphan dose was 150 mg/m 2 Â 4 days. For allo-HCT patients, GVHD prophylaxis consisted of cyclosporine plus methotrexate in 84 patients and cyclosporine alone in the rest. Patients were transplanted in HEPA-filtered or laminar-air flow rooms and received prophylactic acyclovir and fluconazole. All transfusions were irradiated and broad-spectrum empirical antibiotic therapy was started when fever above 38.51C was observed. Informed consent was obtained from the parents or legally authorised representatives, in accordance with institutional policies.
Statistical analysis
Differences between groups were assessed by the w 2 test. Post transplantation outcome, EFS and relapse probabilities (RP) were determined using Kaplan-Meier limit estimates, with a 95% confidence limit derived from the standard errors. Groups were compared using the log-rank test. For analysis of relapse, failure was defined as recurrence of leukaemia at any site: data were censored at the time of death during remission or at the time of last follow-up. For analysis of transplant-related mortality (TRM), failure was defined as death occurring while the patient was in CR. For analysis of EFS, treatment was considered to have failed at the time of relapse or at the time of death from any cause. Multivariate variable analysis was performed using the Cox model.
Results

Patient characteristics and transplant procedure
There were 151 males and 68 females with a median age at transplant of 8.7 years (range 1-16 years). Early relapse occurred in 141 patients (64.4%), and was isolated extramedullary disease in 38 (17.4%). There were no significant differences in the distribution of patients between the allo-HCT and the auto-HCT groups for age at transplant, sex, white blood cell (WBC) count at diagnosis, immunophenotype, relapse timing (ER or LR), or relapse site, neither were there any significant differences in conditioning regimens or length of follow-up. All these data are summarized in Table 1 . Median time from second CR to HCT was 5.2 months for allo-HCT patients and 6.7 months for auto-HCT patients.
Survival
The probability of EFS for the total patient group was 0.3570.03 at 14 years ( Figure 1 ). No significant differences /l in auto-HCT recipients. No differences in EFS were observed between auto-and allo-HCT recipients regarding sex, immunophenotype, or conditioning regimen. EFS was the same for extramedullary relapse for allo-and auto-HSCT recipients (41 vs 52%, P ¼ 0.78). Significantly better EFS was observed in both groups for a subset of patients with the following characteristics: under 10 years of age, WBC o25 Â 10 9 /l and late relapse. EFS in this subset was 0.63 vs 0.29 for the remaining patients (P ¼ 0.0003) (Figure 2) . EFS results are shown in Table 2 .
In the multivariate analysis, factors predictive for an event were early relapse, isolated or combined marrow relapse, and age at transplant over 10 years (Table 3) .
Relapse after transplantation
In total, 107 patients (48.8%) relapsed. Relapse probability for the total patient group at 14 years was 0.57 ( Figure 3) . The longest time to relapse was observed at 48 months of follow-up. Relapse probability was significantly higher in patients who underwent an auto-HCT 0.65 vs 0.42 for allo-HCT (P ¼ 0.002) (Figure 4 ). There were no differences between the two groups of patients in relapse rate according to age, sex or immunophenotype. The probability of relapse was higher for patients with an early relapse and WBC 425 Â 10 9 /l for both groups and in auto-HSCT conditioned with chemotherapy alone.
No significant differences in EFS or probability of relapse were observed between allo-and auto-HSCT patients conditioned with or without irradiation ( Table 4) .
On the multivariate analysis, factors predictive for relapse were WBC count at diagnosis 425 Â 10 9 /l, isolated or combined marrow relapse, early relapse and auto-HCT (Table 5) . 
Death causes and TRM
In the allo-HCT group, 46/90 patients died, 23 (50%) due to disease progression and 22 of transplant-related causes: acute GVHD in nine, infections in eight, hepatic venoocclusive disease (VOD) in three and interstitial pneumonia in two. One patient died from a second tumour (malignant glioma). In the auto-HCT patients, 80/129 (62%) died, 71 due to progressive disease and nine (7%) from transplant-related causes, infections in seven and VOD in two.
A statistically significant difference was observed between allo-and auto-HCT recipients for cause of death (P ¼ 0.001).
TRM rate was similar in patients with or without irradiation in their conditioning regimen, 22 and 23% respectively. VOD was the cause of death in 2.2% of the overall population.
As this was a retrospective study we examined TRM for the allogeneic group in two chronologic periods: 1983-1991 and 1992-1998. We observed that TRM was higher in the first period (26%) than in the second (20%). The difference was statistically significant (P ¼ 0.01) and was due to the lower incidence of acute GVHD grade 3-4 in the second period. 
Discussion
There are few comparative studies on outcome in patients with relapsed ALL treated by allo-or auto-HCT. Some such studies include patients without comparable clinical characteristics, patients who underwent HCT in first CR or in third or subsequent remissions, or only B-cell lineage patients. 23, 30, 31 Direct comparisons of our results with these previous reports are hindered by the heterogeneity of their study populations. In 1995, Uderzo et al 24 published a series of 75 patients with similar characteristics to ours. No significant differences were found for EFS between the allo-and the auto-HCT recipients in either study.
Our series includes the highest number of patients transplanted in second CR reported to date. Following initial treatment with similar BFM-type protocols, all patients received the same chemotherapy after relapse, combined with radiotherapy for CNS and testicular extramedullary disease. Moreover, there were no statistically significant differences between the allo-and the auto-HCT patients regarding age, sex, WBC count at diagnosis, immunophenotype or timing of relapse (ER or LR). Conditioning regimens showed no significant differences between groups. Furthermore, our series has a longer follow-up (median 75 months) than the above-mentioned studies.
Pre-transplant variables such as age, sex, WBC at diagnosis and immunophenotype at diagnosis were assessed. Age o10 years for the allogeneic group (P ¼ 0.05) and WBC o25 Â 10 9 /l (P ¼ 0.02) for the auto-HCT patients were independent variables significantly associated with a higher EFS rate. WBC at diagnosis 425 Â 10 9 /l was significantly associated with a higher relapse rate for auto-HCT patients. Our series did not reproduce the results of previous studies 30 in which a low WBC count was associated with an improved outcome in recipients of allogeneic grafts. However, when patients with both kinds of graft were combined in the present study for multivariate analysis, WBC 425 Â 10 9 /l was a statistically significant predictive factor for relapse.
The role of first remission duration on EFS after auto-HCT has been previously studied. Some studies have found that the duration of initial remission was an important predictor of outcome. 23 However, Kersey et al 30 and Uderzo et al 24 did not find such a relationship. In our series, the length of first CR did not play a statistically significant role in the EFS in allo-HCT recipients, but was significantly associated with a lower EFS rate (P ¼ 0.02) and a higher relapse rate (P ¼ 0.02) in the auto-HCT group.
We identified two subsets of patients, one with a higher probability rate for events and another with a higher EFS probability rate, both in allogeneic and autologous recipients. The first consisted of patients with isolated or combined bone marrow relapse, early relapse and age at transplant over 10 years. The second included patients under 10 years of age, WBC count o25 Â 10 9 /l and late relapse.
Our experience confirms the previous reported differences between allogeneic and autologous transplants for failure patterns (ie a higher TRM and a lower relapse rate in allo-HCT recipients as compared to auto-HCT patients).
There was a higher TRM rate in the allogeneic transplants performed between 1983 and 1991 than in those performed between 1992 and 1998, due to a higher incidence of severe acute GVHD in the first period. This was probably related with the improvement in the prevention and treatment of GVHD in the second chronologic period. 32 The rate of VOD as a cause of death was similar in our series (2.2%) to that reported elsewhere. 33 In total, 14 patients (15%) who underwent an allo-HSCT received donor peripheral blood stem cells. There are published experiences from several groups, which demonstrate that peripheral stem cell allogeneic transplantation is a feasible and safe procedure in children. 34, 35 Whereas there are no comparative studies between allogeneic peripheral and allogeneic marrow cell transplantation, there seems to be a tendency towrds a higher rate of chronic GVHD using peripheral blood stem cells. Mortality is not increased. In fact, patients transplanted with peripheral blood stem cells seem to experience a lower incidence of relapse. 36 The use of unrelated donors (URD) for patients lacking a related matched donor has increased widely over the last decade and is currently in use in our group. Several reports suggest that the results in terms of EFS and TRM are currently similar to those obtained with matched sibling donors. 37, 38 This has been attributed to both the improvement in molecular antigen typing of the URD and the supportive care of the patients. 38 Results of transplants from URD have been compared with autologous grafts. For patients transplanted in second CR, better results were obtained with URD transplants in some subsets of patients: those in CR1 41 year, WBC 450 Â 10 9 /l, performance status X90% and those who have undergone transplantation since 1995. 39 Most reports comparing transplant vs chemotherapy in CNS relapse show a superior outcome for transplanted patients. The current EBMT recommendation is to proceed to transplantation in order to avoid relapse from undiagnosed bone marrow disease. In patients with early CNS and extramedullary relapse in the testes, auto-HCT, a relatively safe therapy, may be a valid treatment option. [40] [41] [42] For late relapses, auto-HSCT provides an effective treatment that is shorter in duration than chemotherapy protocols, which must necessarily be longer. 43, 44 Our results corroborate that auto-HCT is an alternative to other treatments for ALL in children in second CR with a long first remission before relapse. 39 To our knowledge there are no comparative studies between chemotherapy and autografting in ALL in second CR regarding late effects and second malignancies. In our view these are necessary in order to determine the best therapeutic option in this situation. Nonetheless, the rate of second neoplasm observed by our group in patients undergoing autologous transplantation for haematologic malignancies (1.25%) 45 is similar to data reported by other groups utilizing chemotherapy protocols for these diseases. 46, 47 We conclude that our results, and those reported elsewhere, indicate that auto-HSCT is a treatment option in children with ALL after late marrow relapse and after extramedullary relapse. Improvements in the diverse approaches and additional comparative clinical studies might help to define subsets of patients who may experience a better response to a defined transplantation procedure.
